WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...

ZHENJIANG, China--(BUSINESS WIRE)--At 10:16 on January 17, State Grid Zhenjiang Power Supply Company successfully resolved a phase loss fault between Poles 17 and 18 on the 10 kV Antou 292 line of the ...

A new phase shifter does not need clean-room facilities for fabrication, so is inexpensive to manufacture. The liquid-metal enabled phase shifting elements have a 'passive' nature, unlike the 'active' ...

Based on successful Phase 3 trial results, that approval is expected to come over the next few months. This new data, announced in a press release from pharma company Eli Lilly and yet to be ...

A new publication from Opto-Electronic Advances, 10.29026/oea.2023.220085 discuss broadband low-loss all-optical phase modulator using gas-filled hollow-core fiber. Optical phase modulators are key ...

After teasing a small data slice in May, Boehringer Ingelheim is now sharing more on its Zealand Pharma-partnered obesity prospect, with new data showing nearly 19% weight loss in a phase 2 trial.

Eli Lilly (NYSE:LLY) reported full results from a phase 3 trial of its drug Mounjaro (tirzepatide) to treat obesity or overweight in Nature Medicine and also presented it at the ObesityWeek 2023 ...